The medicinal landscape in this country is increasingly characterized by a pattern toward market consolidation, with a handful of prominent companies wielding significant influence. These sector giants, often bolstered by extensive distribution networks and robust brand recognition, present a challenging picture for competition and budget-friendly

The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces increasing concerns about monopolies. A few dominant companies control a significant portion of the market, potentially restricting competition and driving up prices for consumers. This concern raises questions about the long-term impact on patient access